Results 21 to 30 of about 472,711 (314)

Dementia risk in Parkinson’s disease is associated with interhemispheric connectivity loss and determined by regional gene expression

NeuroImage: Clinical, 2020
Parkinson’s dementia is a common and devastating part of Parkinson’s disease. Whilst timing and severity vary, dementia in Parkinson’s is often preceded by visual dysfunction.
Angeliki Zarkali, Peter McColgan, Mina Ryten, Regina H. Reynolds, Louise-Ann Leyland, Andrew J. Lees, Geraint Rees, Rimona S. Weil   +7 more
doaj   +1 more source

Post-Cueing Deficits with Maintained Cueing Benefits in Patients with Parkinson’s Disease Dementia

Frontiers in Neurology, 2014
In Parkinson's disease (PD), internal cueing mechanisms are impaired leading to symptoms like hypokinesia. However, external cues can improve movement execution by using cortical resources. These cortical processes can be affected by cognitive decline in dementia. It is still unclear how dementia in PD influences external cueing.
Gräber-Sultan, Susanne, Liepelt-Scarfone, Inga, Csoti, Ilona, Maetzler, Walter, Sultan, Fahad, Berg, Daniela   +5 more
openaire   +2 more sources

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]

, 2003
Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P.D., Benazzouz, A., LeBas, J.F., Benabid, A.-L., Pollak, P.   +11 more
core   +4 more sources

High risk of developing dementia in Parkinson’s disease: a Swedish registry-based study

Scientific Reports, 2022
Dementia have substantial negative impact on the affected individual, their care partners and society. Persons living with Parkinson’s disease (PwP) are also to a large extent living with dementia. The aim of this study is to estimate time to dementia in
Daniel Oudin Åström, Jacob Simonsen, Lars Lau Raket, Simona Sgarbi, Johan Hellsten, Peter Hagell, Jenny M. Norlin, Klas Kellerborg, Pablo Martinez-Martin, Per Odin   +9 more
doaj   +1 more source

Extended Timed Up and Go assessment as a clinical indicator of cognitive state in Parkinson\u27s disease [PDF]

, 2017
Objective: To evaluate a modified extended Timed Up and Go (extended-TUG) assessment against a panel of validated clinical assessments, as an indicator of Parkinson’s disease (PD) severity and cognitive impairment. Methods: Eighty-seven participants with
Anderton, R, Byrnes, M, Evans, T, Ghosh, S, Jefferson, A, Mastaglia, F, Power, B, Walters, S   +7 more
core   +2 more sources

The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia

Frontiers in Neuroscience, 2018
Dementia, a condition that frequently afflicts patients in advanced stages of Parkinson's disease (PD), results in decreased quality of life and survival time.
Liying Yang, Hongyan Wang, Lijun Liu, A. Xie   +3 more
semanticscholar   +1 more source

SORL1 mutation in a Greek family with Parkinson's disease and dementia

Annals of Clinical and Translational Neurology, 2021
Whole exome sequencing and linkage analysis were performed in a three generational pedigree of Greek origin with a broad phenotypic spectrum spanning from Parkinson’s disease and Parkinson’s disease dementia to dementia of mixed type (Alzheimer disease ...
Georgia Xiromerisiou, Thomas Bourinaris, Henry Houlden, Patrick A. Lewis, Konstantin Senkevich, Monia Hammer, Monica Federoff, Alaa Khan, Cleanthe Spanaki, Georgios M. Hadjigeorgiou, Sevasti Bonstanjopoulou, Liana Fidani, Aleksey Ermolaev, Ziv Gan‐Or, Andrew Singleton, Jana Vandrovcova, John Hardy   +16 more
doaj   +1 more source

Co-designing smart home technology with people with dementia or Parkinson's disease [PDF]

, 2018
Involving users is crucial to designing technology successfully, especially for vulnerable users in health and social care, yet detailed descriptions and critical reflections on the co-design process, techniques and methods are rare.
Bourazeri, A., Stumpf, S.
core   +2 more sources

Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions

Journal of Neurochemistry, 2019
Lewy body diseases share clinical, pathological, genetic and biochemical signatures, and are regarded as a highly heterogeneous group of neurodegenerative disorders.
Lauren Walker, L. Stefanis, J. Attems
semanticscholar   +1 more source

A new visual rating scale for Ioflupane imaging in Lewy body disease

NeuroImage: Clinical, 2018
Background: Dopaminergic loss on 123I-Ioflupane brain imaging is a recognised biomarker for dementia with Lewy bodies. It is usually assessed using a visual rating scale developed for Parkinson's disease, which may not be optimal for dementia with Lewy ...
Jim J. Lloyd, George Petrides, Paul C. Donaghy, Sean J. Colloby, Johannes Attems, John T. O'Brien, Gemma Roberts, Alan J. Thomas   +7 more
doaj   +1 more source